Japan
· Delayed Price · Currency is JPY Astellas Pharma Company Description
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.
The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.
Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution.
Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005.
The company was founded in 1923 and is headquartered in Tokyo, Japan.
| Country | Japan |
| Founded | 1923 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 14,754 |
| CEO | Naoki Okamura |
Contact Details
Address: 2-5-1, Nihonbashi-Honcho Tokyo, 103-8411 Japan | |
| Phone | 81 3 3244 3000 |
| Website | astellas.com |
Stock Details
| Ticker Symbol | 4503 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3942400007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Naoki Okamura | Chief Executive Officer |
| Atsushi Kitamura | Chief Financial Officer |